Myelodysplastic Syndromes (MDS)
2025 Rockville Patient and Family Conference Session: MDS and Transplant
MDS/MPN Overlap
2025 AAMDSIF Bone Marrow Failure Summit Myelodysplastic Syndromes Expert Panel
MDS Virtual Support Group - Evenings- 2025 February
AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with MDS. The group is hosted by AAMDSIF and will be monitored to ensure the privacy and safety of our participants.
STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes
Acute myeloid leukemia Acute myeloid leukemia: (uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of the blood cells.
Genome sequencing in the management of myelodysplastic syndromes and related disorders
Myeloid neoplasms originate from the clonal proliferation of hematopoietic stem cells stem cells: Cells in the body that develop into other cells. There are two main sources of stem cells.
Diagnosis of myelodysplastic syndromes: the classic and the novel
The myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the
Treatment of high-risk myelodysplastic syndromes
Myelodysplastic syndrome (MDS) is considered to be a heterogeneous myeloid malignancy with a common origin in the hematopoietic stem cell compartment and is generally divided into lower- and higher-risk forms. While the treatment goals for lower-risk MDS are to decrease transfusion requirements and transformation into acute leukemia, the major aims for higher-risk MDS are to prolong survival and ultimately cure the patient.
